Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib

Transplant International

Volumn 24, Issue 5, 2011, Pages

  Gerlach, Undine A ^a   Schoenemann, Constanze ^a   Lachmann, Nils ^a   Koch, Martin ^a   Pascher, Andreas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CD4 ANTIBODY; HLA ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INFLIXIMAB; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY SPECIFICITY; CASE REPORT; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE TRANSPLANTATION; LETTER; MEMORY CELL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SALVAGE THERAPY;

ANTIGENS, CD20; BONE MARROW CELLS; BORONIC ACIDS; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; INTESTINES; MIDDLE AGED; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SALVAGE THERAPY; SHORT BOWEL SYNDROME; SYNDECAN-1; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 79953805456     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01203.x     Document Type: Letter

References (15)

1. Ruiz P, Garcia M, Pappas P, et al. Mucosal vascular alterations in isolated small-bowel allografts: relationship to humoral sensitization. Am J Transplant 2003; 3: 43.
2. Troxell ML, Higgins JP, Kambham N, et al. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130: 1489.
3. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
4. Celik A, Saglam F, Cavdar C, et al. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report. Transpl Proc 2008; 40: 302.
5. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibody-secreting cells demonstrating resistance to desensitization with ivIG and rATG. Am J Transplant 2008; 8: 133.
6. Everly JJ, Walsh RC, Alloway RR, et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009; 14: 662.
7. Wang X, Luo H, Cehn H, et al. Role of proteasomes in T-cell activation and proliferation. J Immunol 1998; 160: 788.
8. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
9. Govil A, Walsh RC, Tevar A, et al. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clin Transpl 2009; 443.
10. Island ER, Gonzalez-Pinto IM, Tsai HL, et al. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation. Clin Transpl 2009; 465.
11. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86: 1754.
12. Reutzel-Selke A, Hartmann J, Pratschke J, et al. Cold ischemia does not interfere with tolerance induction. Transplantation 2009; 87: 1116.
13. Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest 2009; 119: 1079.
14. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
15. Walsh RC, Everly JJ, Brailey P, et al. Proteasome-inhibitor based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.